Bone Morphogenetic Protein Market Size was valued at USD 0.51 Billion in 2022. The Bone Morphogenetic Protein Market industry is projected to grow from USD 0.52 Billion in 2023 to USD 0.69 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.40% during the forecast period (2024 - 2032).
The Increasing elderly population, surging incidence of sports-related injuries, and heightened awareness surrounding minimally invasive surgical techniques are expected to be a significant market driver for the Bone Morphogenetic Protein Market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for Bone Morphogenetic Protein is driven by the incidences of sports-related injuries, the growing demand for minimally invasive surgeries, and technological advancements. As per the Centre for Disease Control and Prevention, participation in sports is on the rise globally, leading to an uptick in sports-related injuries.
In a 2021 article titled 'Arm Injury Statistics,' it was noted that approximately 6 million individuals in the United States suffer bone fractures annually, with hip fractures becoming most prevalent among those aged 75 and above. Fractures constitute 16% of all musculoskeletal injuries in the United States each year, with over 40% occurring within home settings. As per the National Safety Council (NSC), exercise equipment accounted for approximately 445,642 injuries in 2022, marking the highest number within any sports and recreation category.
Additionally, the National Highway Transportation Safety Administration (NHTSA) reported that 966 pedal cyclists lost their lives in 2021, reflecting a 1.9 percent increase from 2020. Alcohol was a contributing factor in 36 percent of all fatal crashes involving pedal cyclists in 2021, involving either the motor vehicle driver or the cyclist. Furthermore, urban areas witnessed 85 percent of fatal pedal cyclist crashes during the same year.
Consequently, the escalating occurrence of bone fractures, particularly hip fractures in the aging demographic, necessitates assistance for daily activities, thereby driving the demand for bone morphogenetic protein (BMP) among patients. With the increasing incidence of sports-related injuries, there is a growing need for BMP, which aids in bone formation and caters to individuals requiring such assistance.
Rising incidents of injuries like spinal cord injuries are anticipated to drive the demand for minimally invasive surgeries, consequently fostering market expansion. According to Spinal Cord Injuries Australia (SCIA), a non-governmental organization, around 15,000 individuals in Australia experienced spinal cord injuries (SCIs) in 2020.
Similarly, data from the United Kingdom Spinal Injury Association reveals that approximately 2,500 individuals are either injured or diagnosed with spinal cord injuries annually, contributing to an estimated 50,000 people living with such injuries in the United Kingdom as of 2021.
As a result, it is anticipated that throughout the projection period, demand for the Bone Morphogenetic Protein Market will increase due to the incidences of sports-related injuries, the growing demand for minimally invasive surgeries, and technological advancements. Thus, driving the Bone Morphogenetic Protein Market revenue.
The Bone Morphogenetic Protein Market segmentation, based on Type, includes Recombinant Human Bone Morphogenetic (rhBMP)- 2 and Recombinant Human Bone Morphogenetic Protein (rhBMP) - 7. The Recombinant Human Bone Morphogenetic (rhBMP)- 2 segment dominated the market, accounting for 58% of market revenue. As the global population ages and lifestyle-related diseases become more prevalent, the occurrence of bone disorders like osteoporosis, osteoarthritis, and fractures is on the rise.
This trend has spurred an increasing need for advanced bone grafting materials and therapies to support bone healing and regeneration. In response to this demand, surgeons are progressively integrating rhBMP-2 into a variety of orthopedic and spinal surgeries due to its efficacy in stimulating bone growth and fusion. As surgical methodologies evolve, the adoption of rhBMP-2 is expected to expand even further.
Figure 1: Bone Morphogenetic Protein Market, by Type, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Bone Morphogenetic Protein Market segmentation, based on the Application, includes Spinal Fusion, Trauma, Reconstructive Surgery, and Oral-maxillofacial. The Spinal Fusion segment dominated the market, accounting for 58% of market revenue. According to a study published in the National Library of Medicine in May 2022, every year, an estimated 250,000 to 500,000 individuals worldwide experience spinal cord injuries (SCI).
The leading causes of these injuries often involve preventable factors like violence and automobile accidents. In the United States alone, approximately 17,000 new cases of SCI are reported annually, with an estimated 282,000 individuals living with spinal cord injuries. Notably, the majority of SCI cases resulting from sports-related incidents affect men, and individuals aged 16 to 30 years face the highest risk of sustaining such injuries.
Consequently, the substantial incidence of spinal cord injuries is expected to drive the demand for spinal fusion devices in the coming years. Moreover, the growing preference for minimally invasive surgical approaches, owing to their numerous advantages, is fueling the overall market expansion.
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The anticipated expansion of the Bone Morphogenetic Protein market in North America can be attributed to several key factors. North America boasts a well-established healthcare system featuring top-tier hospitals, clinics, and research institutions. Presently, healthcare expenditure in the United States exceeds USD4.1 trillion, surpassing spending on housing, food, national defense, and automobiles.
Healthcare spending as a percentage of GDP in the United States rose from 15.8% in 2003 to 16% in 2006, with projections indicating a further increase to over 26% by 2022. Per capita healthcare spending in the United States increased from USD6,649 in 2005 to USD7,026 in 2006, reaching USD12,530 between 2006 and 2020, with a projected 9.7% increase in healthcare spending by 2022.
This robust healthcare infrastructure supports the adoption and implementation of advanced medical technologies such as Bone Morphogenetic Protein (BMP) treatments. The BMP market in the region is witnessing expansion, facilitated by the presence of highly skilled healthcare professionals and access to state-of-the-art facilities.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 2: Bone Morphogenetic Protein Market Share By Region 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Bone Morphogenetic Protein Market accounts for the second-largest market share as the aging population in Europe is experiencing a surge in orthopedic ailments like fractures, osteoporosis, and spinal disorders. Between 1990 and 2019, there was a notable 30% rise in musculoskeletal disorders (MSD), affecting 114.3 to 148.3 million Europeans. In 2019, over 66 million Europeans endured chronic low back pain, while 21 million grappled with neck pain.
Additionally, more than 63 million sought treatment for osteoarthritis (OA), with 2 million afflicted by rheumatoid arthritis (RA), 5 million with gout, and 24.5 million experiencing other MSDs. Knee OA impacted over 40 million individuals, hand OA affected 21 million, hip OA affected 6.7 million, and nearly 8 million experienced OA in other areas. Over the past 30 years, there has been a 50% uptick in prevalence, with an annual incidence of 4.8 million cases.
Bone morphogenetic proteins (BMPs) are utilized across various orthopedic procedures to stimulate bone growth and enhance the healing process. Further, the German Bone Morphogenetic Protein Market held the largest market share, and the UK Bone Morphogenetic Protein Market was the fastest-growing market in the European region.
The Asia-Pacific Bone Morphogenetic Protein Market is expected to grow at the fastest CAGR from 2024 to 2032. Several nations across the Asia-Pacific region are experiencing consistent growth in healthcare spending, attributed to factors like economic progress, expanding governmental efforts, and increasing private investments in healthcare infrastructure. In the fiscal year 2022, India allocated approximately 845 billion Indian rupees towards government health expenditure, with around 274 billion Indian rupees directed towards the National Health Mission.
Government budget estimates project that the total health expenditure will surpass 891 billion Indian rupees by fiscal year 2024. This enhanced financial commitment has facilitated wider accessibility to advanced medical treatments, including BMP-based therapies, consequently driving market expansion. Moreover, China’s Bone Morphogenetic Protein Market held the largest market share, and the Indian Bone Morphogenetic Protein Market was the fastest-growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development to expand their product lines, which will help the Bone Morphogenetic Protein market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Bone Morphogenetic Protein industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Bone Morphogenetic Protein industry to benefit clients and increase the market sector. In recent years, the Bone Morphogenetic Protein industry has offered some of the most significant advantages to the field of orthopedic surgery and bone regeneration.
Major players in the Bone Morphogenetic Protein Market, including Johnson & Johnson, Ember Therapeutics Inc., Integra Lifesciences Holdings Corporation, Medtronic PLC, Bio-Techne (R&D Systems, Inc.), Merck KGaA, Pfizer, Inc., Stryker Corporation, Thermo Fischer Scientific, Zimmer Biomet Holdings, Inc are attempting to increase market demand by investing in research and development operations.
Johnson & Johnson engages in the research, development, manufacturing, and sale of pharmaceutical products and medical devices through its various operating companies. Its pharmaceutical offerings encompass treatments for immune disorders, cancer, neurological conditions, infectious diseases, cardiovascular issues, and metabolic disorders. In the realm of medical devices, J&J provides solutions for cardiovascular, orthopedic, neurovascular, general surgery, and vision care applications.
The company distributes its pharmaceutical and medical products to a wide range of entities, including retailers, wholesalers, healthcare professionals, and hospitals across different regions, including the US, Europe, Asia-Pacific, Africa, Latin America, and the Western Hemisphere (excluding the US). Headquartered in New Brunswick, New Jersey, USA, J&J maintains a global presence.
Pfizer is involved in the discovery, development, manufacturing, and commercialization of biopharmaceuticals across various therapeutic areas. Its product portfolio encompasses treatments for cardiovascular and metabolic disorders, pain management, women's health, cancer, inflammation, immune-related conditions, and rare diseases. Additionally, Pfizer offers sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs), and contract manufacturing services.
The company distributes its products through a wide network, including wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies, and pharmacies. With major manufacturing facilities located in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US, Pfizer serves markets across North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Headquartered in New York, USA, Pfizer operates on a global scale.
Bone Morphogenetic Protein Industry Developments
August 2022: Orthofix Medical Inc. formed a strategic partnership with CGBio to advance the clinical development and commercialization of Novosis recombinant human bone morphogenetic protein-2 (rhBMP-2) bone growth materials and other forthcoming tissue regenerative solutions within the United States and Canadian markets.
September 2019: FDA approval was granted to Medtronic for the utilization of Infuse bone graft, enabling its application in Transforaminal Lumbar Interbody Fusion (TLIF) spine procedures
| Market Size 2022 | USD 0.51 Billion |
| Market Size 2023 | USD 0.52 Billion |
| Market Size 2032 | USD 0.69 Billion |
| Compound Annual Growth Rate (CAGR) | 3.40% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea |
| Key Companies Profiled | Johnson & Johnson, Ember Therapeutics Inc., Integra Lifesciences Holdings Corporation, Medtronic PLC, Bio-Techne (R&D Systems, Inc.), Merck KGaA, Pfizer, Inc., Stryker Corporation, Thermo Fischer Scientific, Zimmer Biomet Holdings, Inc |
| Key Market Opportunities | · Rising Technological Development and suitable reimbursement policies |
| Key Market Dynamics | · The Rise in Sports Regarding Injuries Around the World |
Frequently Asked Questions (FAQ) :
The Bone Morphogenetic Protein Market size was valued at USD 0.52 Billion in 2023.
The Bone Morphogenetic Protein Market is projected to grow at a CAGR of 3.40% during the forecast period 2024-2032.
North America had the largest share of the global market.
The key players in the market are Johnson & Johnson, Ember Therapeutics Inc., Integra Lifesciences Holdings Corporation, Medtronic PLC, Bio-Techne (R&D Systems, Inc.), Merck KGaA, Pfizer, Inc., Stryker Corporation, Thermo Fischer Scientific, Zimmer Biomet Holdings, Inc, and others.
The Recombinant Human Bone Morphogenetic (rhBMP)- 2 segment dominated the market in 2023.
The Spinal Fusion segment had the largest share of the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
